OncoMatch/Clinical Trials/NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Is NCT04613596 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2/3 trial studies multiple treatments including Adagrasib and Pembrolizumab for advanced non-small cell lung cancer.
Treatment: Adagrasib · Pembrolizumab — The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12c
Prior therapy
Cannot have received: systemic therapy for locally advanced or metastatic nsclc
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- 21st Century Oncology of Jacksonville - North Lee Street · Jacksonville, Florida
- Local Institution - 007-562-D · Jacksonville, Florida
- Local Institution - 007-562-E · Jacksonville, Florida
- Local Institution - 007-562-G · Jacksonville, Florida
- Local Institution - 007-829 · Jacksonville, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04613596 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy for locally advanced or metastatic nsclc disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12c is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify